Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Phase of Trial: Phase IV
Latest Information Update: 27 Nov 2018
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms FARAONIC
- Sponsors Bayer
- 19 Nov 2018 Planned End Date changed from 30 Nov 2020 to 30 Dec 2020.
- 19 Nov 2018 Planned primary completion date changed from 30 Sep 2020 to 30 Nov 2020.
- 10 Aug 2018 Planned End Date changed from 30 Aug 2020 to 30 Nov 2020.